Zacks Rating on Pernix Therapeutics Holdings (PTX)

Pernix Therapeutics Holdings (PTX) : 3 analysts are covering Pernix Therapeutics Holdings (PTX) and their average rating on the stock is 3, which is read as a Hold. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Shares of Pernix Therapeutics Holdings, Inc. rose by 16.88% in the last five trading days and 36.98% for the last 4 weeks. Pernix Therapeutics Holdings, Inc. is up 55.21% in the last 3-month period. Year-to-Date the stock performance stands at -74.27%. Pernix Therapeutics Holdings (NASDAQ:PTX): On Tuesdays trading session , Opening price of the stock was $0.753 with an intraday high of $0.769. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.704. However, the stock managed to close at $0.759, a loss of 3.58% for the day. On the previous day, the stock had closed at $0.7872. The total traded volume of the day was 8,814,036 shares.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.